Johnson & Johnson (JNJ)
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson: Tracking Well Above The Industry
In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year, thanks in part to its label expansions. Moreover, on November 8, 2024, the company announced the filing of regulatory applications to the FDA and EMA seeking approval of Darzalex Faspro for the treatment of high-risk smoldering MM.
Johnson & Johnson Enters Oversold Territory
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
US FDA approves Johnson & Johnson's device for heart condition
The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of heart condition, the company said on Thursday.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth
J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and MedTech, despite ongoing challenges. The company updated its full-year guidance, showing optimism despite headwinds like talc litigation and STELARA generic competition, maintaining strong cash flow and dividend payouts. New growth opportunities in oncology and MedTech segments, along with strategic acquisitions, are expected to offset potential declines in STELARA sales due to generics.
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Johnson & Johnson's JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue KVUE, but those days are behind, and business growth is still ahead.
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike
Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.
What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.42 per share, compared to our estimates of $22.2 billion and $2.20, respectively.
This Magnificent Dividend Stock Is as Healthy as It Gets
Johnson & Johnson's latest financial checkup shows it's still in excellent health.
